#Germany #Scinai Immunotherapeutics #dermatology #Prof. Michael Schön #Göttingen

Prof. Michael Schön Joins Scinai Immunotherapeutics' Advisory Board

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company with a focus on developing treatments for inflammation and immunological disorders, has recently announced a significant addition to its Scientific Advisory Board. Prof. Michael Schön, a respected authority in dermatology and the Director of Dermatology and Venereology at the University Medical Center Göttingen in Germany, has been appointed to this crucial role.

About Prof. Michael Schön

Prof. Schön brings a wealth of knowledge and experience to Scinai, having dedicated his career to advancing dermatological research. In addition to his editorial leadership as the former Editor-in-Chief of the Journal of the German Dermatological Society, he holds esteemed positions within various professional organizations, including serving as the Secretary General and Vice President of the European Dermatology Forum (EDF).

Notably, Prof. Schön has an impressive academic background, earning his medical degree from the University of Ulm. His diverse experience spans several prestigious institutions, including the Free University of Berlin and Harvard Medical School, and he has held a professorship in Experimental Biomedicine at the University of Würzburg. His extensive research has earned him numerous accolades, particularly regarding immune responses in inflammatory skin diseases.

Contribution to Scinai's Mission

In his new role at Scinai, Prof. Schön is enthusiastic about contributing to the company’s innovative pipeline of therapeutics aimed at addressing unmet medical needs in chronic inflammatory conditions. He highlighted the potential of Scinai's targeted immunotherapeutic approaches to bring about significant advancements in precision medicine for skin diseases and other immunologically mediated conditions.

Prof. Schön stated, "It is a great pleasure and honor for me to be part of the advisory board for Scinai and to contribute to the success of their highly innovative pipeline. Many areas of chronic inflammatory skin diseases, as well as other organ systems with immunologically mediated diseases, present a significant unmet medical need. In my view, Scinai's therapeutic approaches have excellent potential."

The Future of Scinai Immunotherapeutics

Amir Reichman, CEO of Scinai, expressed his excitement about Prof. Schön's appointment, stating, "We are thrilled to welcome Prof. Schön, a world-class expert in dermatology, particularly in psoriasis and atopic dermatitis, to our Scientific Advisory Board. His extensive experience as a dermatologist, along with over 440 scientific publications, will be invaluable as we progress with our pipeline of innovative biological products."

In addition, this new appointment coincides with the recognition of Dr. Jonathan Sadeh, another member of the advisory board, who recently stepped into the role of Chief Scientific Officer and Chief Medical Officer of Bausch Health. Scinai emphasizes the importance of having prestigious and knowledgeable experts guiding its research and development efforts, which is crucial for the company's growth and impact in the biopharmaceutical industry.

Scinai's Business Focus

Scinai Immunotherapeutics operates with two key business units: one dedicated to the in-house development of inflammation and immunology biological therapeutic products, starting with their innovative pipeline of nanosized VHH antibodies that target diseases with significant medical needs. The other unit provides CDMO services that encompass everything from biological drug development to clinical trial design and execution. With this strong focus on innovation and expert collaboration, Scinai is well-positioned to make meaningful contributions to the field of immunology and dermatology.

For more information about Scinai Immunotherapeutics and their ongoing projects, you can visit their official website www.scinai.com.